InBioGen Co Ltd (101140) - Net Assets
Based on the latest financial reports, InBioGen Co Ltd (101140) has net assets worth ₩170.78 Billion KRW (≈ $115.73 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩173.22 Billion ≈ $117.39 Million USD) and total liabilities (₩2.44 Billion ≈ $1.65 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 101140 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩170.78 Billion |
| % of Total Assets | 98.59% |
| Annual Growth Rate | 40.93% |
| 5-Year Change | 105.17% |
| 10-Year Change | 1949.27% |
| Growth Volatility | 66.54 |
InBioGen Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how InBioGen Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 101140 company net worth.
Annual Net Assets for InBioGen Co Ltd (2013–2024)
The table below shows the annual net assets of InBioGen Co Ltd from 2013 to 2024. Also explore net asset growth rate of InBioGen Co Ltd to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩159.84 Billion ≈ $108.32 Million |
+7.50% |
| 2023-12-31 | ₩148.68 Billion ≈ $100.76 Million |
+42.40% |
| 2022-12-31 | ₩104.42 Billion ≈ $70.76 Million |
-41.35% |
| 2021-12-31 | ₩178.02 Billion ≈ $120.64 Million |
+128.51% |
| 2020-12-31 | ₩77.91 Billion ≈ $52.80 Million |
+18.05% |
| 2019-12-31 | ₩66.00 Billion ≈ $44.72 Million |
+182.62% |
| 2018-12-31 | ₩23.35 Billion ≈ $15.83 Million |
+106.21% |
| 2017-12-31 | ₩11.32 Billion ≈ $7.67 Million |
+96.90% |
| 2016-12-31 | ₩5.75 Billion ≈ $3.90 Million |
-26.26% |
| 2015-12-31 | ₩7.80 Billion ≈ $5.29 Million |
+89.11% |
| 2014-12-31 | ₩4.12 Billion ≈ $2.79 Million |
+12.38% |
| 2013-12-31 | ₩3.67 Billion ≈ $2.49 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to InBioGen Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5934138426000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩20.07 Billion | 12.56% |
| Other Components | ₩139.77 Billion | 87.44% |
| Total Equity | ₩159.84 Billion | 100.00% |
InBioGen Co Ltd Competitors by Market Cap
The table below lists competitors of InBioGen Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PT Sarimelati Kencana Tbk
JK:PZZA
|
$33.11 Million |
|
Rossmax International Ltd
TWO:4121
|
$33.11 Million |
|
Workhorse Group Inc
NASDAQ:WKHS
|
$33.11 Million |
|
Marti Otel Isletmeleri AS
IS:MARTI
|
$33.12 Million |
|
Destini Bhd
KLSE:7212
|
$33.08 Million |
|
Axita Cotton Limited
NSE:AXITA
|
$33.07 Million |
|
Vate Technology Co Ltd
TWO:5344
|
$33.04 Million |
|
Success Prime Corp
TW:2496
|
$33.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in InBioGen Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 148,684,869,120 to 159,836,576,100, a change of 11,151,706,980 (7.5%).
- Net income of 16,122,333,880 contributed positively to equity growth.
- Other factors decreased equity by 4,970,626,900.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩16.12 Billion | +10.09% |
| Other Changes | ₩-4.97 Billion | -3.11% |
| Total Change | ₩- | 7.50% |
Book Value vs Market Value Analysis
This analysis compares InBioGen Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.31x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 10.21x to 0.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩479.09 | ₩4890.00 | x |
| 2018-12-31 | ₩835.76 | ₩4890.00 | x |
| 2019-12-31 | ₩1709.47 | ₩4890.00 | x |
| 2020-12-31 | ₩1542.51 | ₩4890.00 | x |
| 2021-12-31 | ₩3401.17 | ₩4890.00 | x |
| 2022-12-31 | ₩746.73 | ₩4890.00 | x |
| 2023-12-31 | ₩14891.16 | ₩4890.00 | x |
| 2024-12-31 | ₩16008.03 | ₩4890.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently InBioGen Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.09%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 228.98%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.02x
- Recent ROE (10.09%) is above the historical average (-22.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -37.61% | -17.33% | 0.80x | 2.73x | ₩-1.75 Billion |
| 2014 | -39.10% | -13.71% | 1.65x | 1.72x | ₩-2.02 Billion |
| 2015 | -72.91% | -64.14% | 0.61x | 1.87x | ₩-6.47 Billion |
| 2016 | -39.22% | -19.54% | 0.93x | 2.15x | ₩-2.83 Billion |
| 2017 | -10.69% | -17.11% | 0.53x | 1.18x | ₩-2.34 Billion |
| 2018 | 7.13% | 21.99% | 0.31x | 1.04x | ₩-671.17 Million |
| 2019 | 19.89% | 133.98% | 0.11x | 1.38x | ₩6.52 Billion |
| 2020 | -57.86% | -441.17% | 0.11x | 1.24x | ₩-52.87 Billion |
| 2021 | 52.87% | 898.07% | 0.04x | 1.54x | ₩76.32 Billion |
| 2022 | -114.63% | -1049.54% | 0.08x | 1.36x | ₩-130.13 Billion |
| 2023 | 7.63% | 181.77% | 0.04x | 1.02x | ₩-3.52 Billion |
| 2024 | 10.09% | 228.98% | 0.04x | 1.02x | ₩138.68 Million |
Industry Comparison
This section compares InBioGen Co Ltd's net assets metrics with peer companies in the Footwear & Accessories industry.
Industry Context
- Industry: Footwear & Accessories
- Average net assets among peers: $216,778,568,226
- Average return on equity (ROE) among peers: 6.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| InBioGen Co Ltd (101140) | ₩170.78 Billion | -37.61% | 0.01x | $33.09 Million |
| Samyang Tongsang Co. Ltd. (002170) | $184.69 Billion | 5.30% | 0.26x | $97.51 Million |
| Hwaseung Industries Co Ltd (006060) | $453.41 Billion | 13.00% | 1.80x | $77.29 Million |
| Uni Chem (011330) | $120.70 Billion | -8.47% | 0.54x | $254.40 Million |
| Baiksan (035150) | $92.03 Billion | -2.79% | 0.77x | $144.83 Million |
| Gumho NT Co Ltd (130500) | $30.50 Billion | 8.00% | 0.55x | $18.27 Million |
| JS Corp (194370) | $98.64 Billion | 19.88% | 0.61x | $255.26 Million |
| Hwaseung Enterprise Co Ltd (241590) | $537.46 Billion | 7.46% | 1.15x | $114.97 Million |
About InBioGen Co Ltd
INBIOGEN Co., Ltd. engages in the manufacture and distribution of footwear products in South Korea. It is also involved in distribution of wood pellets; kiosk; and food and beverage businesses. The company was formerly known as BTONE CO.,Ltd. INBIOGEN Co., Ltd. was founded in 1949 and is headquartered in Seoul, South Korea.